» Articles » PMID: 19219043

A TARBP2 Mutation in Human Cancer Impairs MicroRNA Processing and DICER1 Function

Abstract

microRNAs (miRNAs) are small noncoding RNAs that regulate gene expression by targeting messenger RNA (mRNA) transcripts. Recently, a miRNA expression profile of human tumors has been characterized by an overall miRNA downregulation. Explanations for this observation include a failure of miRNA post-transcriptional regulation, transcriptional silencing associated with hypermethylation of CpG island promoters and miRNA transcriptional repression by oncogenic factors. Another possibility is that the enzymes and cofactors involved in miRNA processing pathways may themselves be targets of genetic disruption, further enhancing cellular transformation. However, no loss-of-function genetic alterations in the genes encoding these proteins have been reported. Here we have identified truncating mutations in TARBP2 (TAR RNA-binding protein 2), encoding an integral component of a DICER1-containing complex, in sporadic and hereditary carcinomas with microsatellite instability. The presence of TARBP2 frameshift mutations causes diminished TRBP protein expression and a defect in the processing of miRNAs. The reintroduction of TRBP in the deficient cells restores the efficient production of miRNAs and inhibits tumor growth. Most important, the TRBP impairment is associated with a destabilization of the DICER1 protein. These results provide, for a subset of human tumors, an explanation for the observed defects in the expression of mature miRNAs.

Citing Articles

Deciphering the multifaceted role of microRNAs in hepatocellular carcinoma: Integrating literature review and bioinformatics analysis for therapeutic insights.

Rahdan F, Saberi A, Saraygord-Afshari N, Hadizadeh M, Fayeghi T, Ghanbari E Heliyon. 2024; 10(20):e39489.

PMID: 39498055 PMC: 11532857. DOI: 10.1016/j.heliyon.2024.e39489.


Research progress and perspectives of noncoding RNAs in adrenocortical carcinoma: A review.

Xu C, Xu P, Zhang J, He S, Hua T, Huang A Medicine (Baltimore). 2024; 103(4):e36908.

PMID: 38277554 PMC: 10817030. DOI: 10.1097/MD.0000000000036908.


miRNA-Based Technologies in Cancer Therapy.

Pagoni M, Cava C, Sideris D, Avgeris M, Zoumpourlis V, Michalopoulos I J Pers Med. 2023; 13(11).

PMID: 38003902 PMC: 10672431. DOI: 10.3390/jpm13111586.


Surmounting Cancer Drug Resistance: New Perspective on RNA-Binding Proteins.

Feng Y, Zhu S, Liu T, Zhi G, Shao B, Liu J Pharmaceuticals (Basel). 2023; 16(8).

PMID: 37631029 PMC: 10458901. DOI: 10.3390/ph16081114.


To Assess the Role of microRNA-451 in the Progression and Metastasis of Colorectal Cancer.

Chen H, Yao J, Shan Z, Wei Y, You S, Li D Appl Biochem Biotechnol. 2023; 196(2):1044-1057.

PMID: 37318687 DOI: 10.1007/s12010-023-04538-2.


References
1.
Karube Y, Tanaka H, Osada H, Tomida S, Tatematsu Y, Yanagisawa K . Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci. 2005; 96(2):111-5. PMC: 11158408. DOI: 10.1111/j.1349-7006.2005.00015.x. View

2.
Hammond S . MicroRNAs as tumor suppressors. Nat Genet. 2007; 39(5):582-3. DOI: 10.1038/ng0507-582. View

3.
Schmittgen T, Jiang J, Liu Q, Yang L . A high-throughput method to monitor the expression of microRNA precursors. Nucleic Acids Res. 2004; 32(4):e43. PMC: 390315. DOI: 10.1093/nar/gnh040. View

4.
Cummins J, He Y, Leary R, Pagliarini R, Diaz Jr L, Sjoblom T . The colorectal microRNAome. Proc Natl Acad Sci U S A. 2006; 103(10):3687-92. PMC: 1450142. DOI: 10.1073/pnas.0511155103. View

5.
Sander S, Bullinger L, Klapproth K, Fiedler K, Kestler H, Barth T . MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood. 2008; 112(10):4202-12. DOI: 10.1182/blood-2008-03-147645. View